The panel will run alongside Ipsos’ therapy monitor, and comprises MS patients in France, Germany, Italy, Spain, UK and US. Panellists will participate in a range of tasks throughout the year, both syndicated and proprietary, moderated by MS specialists from Ipsos Healthcare.

Subscribers will be able to explore key topics throughout the year and ask questions of the community as they arise.

The panel is the latest addition to the company’s Global Patient Centre of Excellence.

Paul O’Meara, head of real world evidence in autoimmune diseases at Ipsos Healthcare, said: "As patients move from recipients to participants, there is an imperative for pharma to put patients at the heart of current and future business models.

"Designed with this objective in mind, the MS Community will enable our clients to identify unmet patient needs, optimise their patient communications, assess new ideas, and develop personalised medicine strategies for those living with MS."